Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Beckman Coulter, Inc.
A precursor of PSA detects more aggressive disease
July 30th, 2003
An inactive precursor form of PSA, prostate specific antigen, may prove better than the current standard of testing at detecting prostate cancer and identifying more aggressive forms of the disease, according to a study presented at the 94th Annual Meeting of the American Association for Cancer Research (AACR). PSA, an enzyme normally secreted by the prostate, is a well-known marker used to detect the presence of prostate cancer. As prostate cancer develops, a greater amount of PSA is released into the bloodstream. Current PSA tests measure "free" and "bound" PSA, yet often fail to distinguish between slow-growing cancers, which may take years to become...
Source: Biotech Week (2003-07-30)
|
